Guanylin GUCY2C axis in Colorectal Cancer Initiation
鸟苷素 GUCY2C 轴在结直肠癌发生中的作用
基本信息
- 批准号:9237630
- 负责人:
- 金额:$ 37.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-01-01 至 2021-12-31
- 项目状态:已结题
- 来源:
- 关键词:Alpha CellAutomobile DrivingBinding SitesCarcinogensChemopreventionChronicColon CarcinomaColorectalColorectal CancerConstipationDNA Sequence AlterationDataDiseaseElementsEpithelialEventFRAP1 geneFunctional disorderGastrointestinal Hormone ReceptorsGene MutationGenetic TranscriptionHormonesHumanIn VitroInduced MutationIntestinal NeoplasmsLigandsLinkMediatingMessenger RNAMolecularMusMutationNuclear TranslocationOncogenicOralOrganoidsOutcomePolyubiquitinationPreventionProcessProteinsProto-Oncogene Proteins c-aktSignal PathwaySignal TransductionSurfaceTestingTranscriptTransgenesTransgenic MiceTransgenic OrganismsTranslationsTumor Suppressor Proteinsbasebeta catenincancer cellcancer initiationcolorectal cancer preventiongene productguanylinin vivoinsightmouse modelmutantmutant mouse modelnovelpreventprogramspromoterreceptorreconstitutionrepairedtranscription factortumortumor initiationtumorigenesis
项目摘要
PROJECT SUMMARY/ABSTRACT
Mutations in APC (~85%) or β-catenin (~5%) initiate >90% of sporadic colorectal cancers. These mutations
produce β-catenin accumulation and nuclear translocation, activating Tcf which drives transcriptional programs
underlying tumorigenesis. GUCY2C is the intestinal receptor for the hormone guanylin expressed in
colorectum. In the healthy state, guanylin-GUCY2C signaling regulates homeostatic processes that organize
the crypt-surface axis, in part through an unknown mechanism which blocks β-catenin accumulation. Of
significance, guanylin is the most commonly lost mRNA transcript in colorectal cancer. Hormone loss, which
silences GUCY2C, occurs at the earliest stages of transformation through an unknown mechanism conserved
in mice and humans. Preliminary studies reveal that guanylin loss is mediated by mutant APC-β-catenin-Tcf
signaling. Moreover, transgenic guanylin expression eliminated carcinogen-induced tumor formation in
mice. Based on these observations, we propose that mutant APC-β-catenin-Tcf signaling transcriptionally
silences guanylin as an obligatory step in tumorigenesis because guanylin-GUCY2C signaling blocks β-catenin
accumulation required for transformation. The correlative chemoprevention hypothesis suggests that guanylin
replacement should eliminate tumorigenesis driven by APC-β-catenin signaling. Here, the Pathophysiologic
Aim will identify the transcriptional mechanisms mediating guanylin loss by mutant APC-β-catenin-Tcf. These
studies will establish a novel molecular link between mutant APC-β-catenin-Tcf signaling, guanylin
suppression, and GUCY2C silencing which is obligatory for tumorigenesis. The Mechanistic Aim tests the
hypothesis that guanylin is lost because GUCY2C blocks β-catenin accumulation required for tumorigenesis.
These studies will demonstrate that the guanylin-GUCY2C axis restricts β-catenin accumulation by blocking
protein translation (synthesis) and inducing proteosomal degradation. The Prevention Aim tests the
hypothesis that colorectal cancer reflects suppression of guanylin expression and GUCY2C signaling which
can be overcome by hormone replacement. These studies will demonstrate the ability of transgenic guanylin
expression to repair oncogenic β-catenin signaling, reconstitute endogenous GUCY2C hormone expression,
and prevent tumorigenesis following biallelic APC inactivation in mice. Together, these studies will reveal a
previously unanticipated required step in colorectal cancer initiation involving guanylin loss and GUCY2C
silencing. They will shift the pathophysiological paradigm for colorectal cancer from a disease of irreversible
gene mutations to one of reversible hormone insufficiency. Mechanistically, they will identify a unique
vulnerability at the apex of the oncogenic cascade in which β-catenin-dependent events required for
tumorigenesis can be overcome by GUCY2C signaling. Moreover, they will establish the proof of principle
that colorectal cancer can be prevented by hormone replacement. The potential for immediate translation is
underscored by the approval of the oral GUCY2C ligand linaclotide to treat chronic constipation.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SCOTT A WALDMAN其他文献
SCOTT A WALDMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SCOTT A WALDMAN', 18)}}的其他基金
Neuroprotection by the GUCY2C gut-brain axis in Parkinson's disease
GUCY2C 肠脑轴对帕金森病的神经保护作用
- 批准号:
10740951 - 财政年份:2023
- 资助金额:
$ 37.2万 - 项目类别:
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation
(PQ1)GUCY2C激素损失将APC-β-连环蛋白突变转化为上皮转化
- 批准号:
9922880 - 财政年份:2016
- 资助金额:
$ 37.2万 - 项目类别:
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation
(PQ1)GUCY2C激素损失将APC-β-连环蛋白突变转化为上皮转化
- 批准号:
9101320 - 财政年份:2016
- 资助金额:
$ 37.2万 - 项目类别:
GUCY2C hormone signaling at the intersection of obesity and colorectal cancer(PQ1
肥胖与结直肠癌交叉点上的 GUCY2C 激素信号传导(PQ1
- 批准号:
8680189 - 财政年份:2012
- 资助金额:
$ 37.2万 - 项目类别:
GUCY2C hormone signaling at the intersection of obesity and colorectal cancer(PQ1
肥胖与结直肠癌交叉点上的 GUCY2C 激素信号传导(PQ1
- 批准号:
8517056 - 财政年份:2012
- 资助金额:
$ 37.2万 - 项目类别:
GUCY2C hormone signaling at the intersection of obesity and colorectal cancer(PQ1
肥胖与结直肠癌交叉点上的 GUCY2C 激素信号传导(PQ1
- 批准号:
8895861 - 财政年份:2012
- 资助金额:
$ 37.2万 - 项目类别:
Occult lymph node metastases and racial disparities in colon cancer outcomes
结肠癌结果中的隐匿性淋巴结转移和种族差异
- 批准号:
7828432 - 财政年份:2009
- 资助金额:
$ 37.2万 - 项目类别:
Occult lymph node metastases and racial disparities in colon cancer outcomes
结肠癌结果中的隐匿性淋巴结转移和种族差异
- 批准号:
7941015 - 财政年份:2009
- 资助金额:
$ 37.2万 - 项目类别:
Guanylyl Cyclase C in Blood and Colorectal Cancer
血液和结直肠癌中的鸟苷酸环化酶 C
- 批准号:
6772420 - 财政年份:2003
- 资助金额:
$ 37.2万 - 项目类别:
Guanylyl Cyclase C in Blood and Colorectal Cancer
血液和结直肠癌中的鸟苷酸环化酶 C
- 批准号:
6685481 - 财政年份:2003
- 资助金额:
$ 37.2万 - 项目类别:
相似海外基金
Establishment of a method for evaluating automobile driving ability focusing on frontal lobe functions and its application to accident prediction
以额叶功能为中心的汽车驾驶能力评价方法的建立及其在事故预测中的应用
- 批准号:
20K07947 - 财政年份:2020
- 资助金额:
$ 37.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of the Effectiveness of Multi-Professional Collaborative Assessment of Cognitive Function and Automobile Driving Skills and Comprehensive Support
认知功能与汽车驾驶技能多专业协同评估效果评价及综合支持
- 批准号:
17K19824 - 财政年份:2017
- 资助金额:
$ 37.2万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Development of Flexible Automobile Driving Interface for Disabled People
残疾人灵活汽车驾驶界面开发
- 批准号:
25330237 - 财政年份:2013
- 资助金额:
$ 37.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Automobile driving among older people with dementia: the effect of an intervention using a support manual for family caregivers
患有痴呆症的老年人的汽车驾驶:使用家庭护理人员支持手册进行干预的效果
- 批准号:
23591741 - 财政年份:2011
- 资助金额:
$ 37.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)